Chemical Namegivosiran
Dosage FormInjectable (subcutaneous; 189 mg/mL)
Drug ClassOligonucleotides
CompanyAlnylam Pharmaceuticals Inc.
Approval Year2019


  • Givlaari is indicated for the treatment of adults with acute hepatic porphyria (AHP).
Last updated on 10/20/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Givlaari (givosiran) Prescribing Information2019Alnylam Pharmaceuticals
Document TitleYearSource
Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria.2020New England Journal of Medicine